UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF MARCH 2020
COMMISSION FILE NUMBER 001-39081
BioNTech SE
(Translation of registrant’s name into English)
An der Goldgrube 12
D-55131 Mainz
Germany
+49 6131-9084-0
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K
On March 16, 2020, BioNTech SE (the “Company”) issued a press release, attached hereto as Exhibit 99.1, announcing that the Company entered into an agreement with Fosun Pharma, a leading healthcare group founded in Shanghai, to jointly conduct clinical trials and commercialize the Company’s mRNA vaccine candidate BNT162 in China for the prevention of COVID-19.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BioNTech SE | |
|
|
|
|
|
|
| By: | /s/ Dr. Sierk Poetting |
|
| Name: Dr. Sierk Poetting |
|
| Title: Chief Financial Officer |
Date: March 16, 2020
|
|
Exhibit | Description of Exhibit |
|
|
99.1 | Press Release dated March 16, 2020 - BioNTech and Fosun Pharma form COVID-19 vaccine strategic alliance in China. |
|
|